非酒精性单纯性脂肪肝变中血脂、尿酸水平检测的临床意义
|
摘要
目的探讨非酒精性单纯性脂肪肝变中血脂、尿酸水平检测的临床意义。方法选取2016年10月～2018年10月在甘肃宝石花医院就诊的198例门诊及住院的非酒精性单纯性脂肪肝变患者作为实验组,选取同期来我院体健的68例无脂肪肝健康人群作为对照组。分析两组的特点,检测其血脂和尿酸浓度。结果实验组的血脂和尿酸指标升高比例高于对照组,差异有统计学意义(P<0.05)。结论血脂和尿酸可能参与非酒精性单纯性脂肪肝变的发病过程,具有重要的临床意义。
Objective To explore the clinical significance of detection of serum lipid and uric acid levels in non-alcoholic simple fatty liver(SFL) disease. Methods A total of 198 cases of non-alcoholic SFL patients with outpatients and inpatients from October 2016 to October 2018 were selected as the experimental group, and 68 cases of healthy people without fatty liver at the same period were selected as the control group. The characteristics of the two groups were analyzed, and the concentrations of serum lipid and uric acid in the two group were measured. Results The increase proportion of indexes of serum lipid and uric acid in the experimental group were higher than those in the control group,the differences were statistically significant(P<0.05). Conclusion Serum lipid and uric acid may be involved in the pathogenesis of non-alcoholic SFL disease and have important clinical significance.
Objective To explore the clinical significance of detection of serum lipid and uric acid levels in non-alcoholic simple fatty liver(SFL) disease. Methods A total of 198 cases of non-alcoholic SFL patients with outpatients and inpatients from October 2016 to October 2018 were selected as the experimental group, and 68 cases of healthy people without fatty liver at the same period were selected as the control group. The characteristics of the two groups were analyzed, and the concentrations of serum lipid and uric acid in the two group were measured. Results The increase proportion of indexes of serum lipid and uric acid in the experimental group were higher than those in the control group,the differences were statistically significant(P<0.05). Conclusion Serum lipid and uric acid may be involved in the pathogenesis of non-alcoholic SFL disease and have important clinical significance.
引文
[1]Amedeo L,Fabio N,Mauro M,et al.Nonalcoholic fatty liver disease:Evolving paradigms[J].World J Gastroenterol,2017,23(36):6571-6592.
[2]Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia[J].J Hepatol,2017,67(4):862-873.
[3]Chao Y,Yang SJ,Xu WW,et al.Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population:a retrospective cohort study[J].PLoS One,2017,12(5):e0177249.
[4]中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].现代医药卫生,2018,34(5):641-649.
[5]Ivana M,Sandra M,Tamara TW,et al.Nonalcoholic fatty liver disease——a multisystem disease?[J].World J Gastroenterol,2016,22(43):9488-9505.
[6]Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.
[7]Zhu JZ,Zhou QY,Wang YE,et al.Prevalence of fatty liver disease and the economy in China:a systematic review[J].World J Gastroenterol,2015,21(18):5695-5706.
[8]Kwok R,Choi KC,Wong GL,et al.Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:a prospective cohort study[J].Gut,2016,65(8):1359-1368.
[9]Zhang RN,Zhang RD,Mi YQ,et al.APOC3 rs2070666 is associated with the severity of hepatic steatosis independently of PNPLA3 rs738409 in Chinese patients with nonalcoholic fatty liverdiseases[J].Dig Dis Sci,2016,61(8):2284-2293.
[10]Bedossa P,Flip Pathology Consortium.Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis,activity,and fibrosis(SAF)score in the evaluation of biopsies of nonalcoholic fatty liver disease[J].Hepatology,2014,60(2):565-575.
[11]Chitturi S,Wong VW,Chan WK,et al.The Asia Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 2:management and special groups[J].J Gastroenterol Hepatol,2018,33(1):86-98.
[12]Xu L,Lu W,Li P,et al.A comparison of hepatic steatosis index,controlled attenuation parameter,and ultrasound as noninvasive diagnostic tools for hepatic steatosis in patients with biopsy-proven chronic hepatitis B[J].Dig Liver Dis,2017,49(8):910-917.
[13]Zhang HJ,Pan LL,Ma ZM,et al.Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults:a 1-year follow up study[J].Diabetes Obes Metab,2017,19(2):284-289.
[14]Zheng XY,Gong LL,Luo R,et al.Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J].Lipids Health Dis,2017,16(10):202.
[15]Rosa L,Giuseppina P,Silvia F.Role of serum uric acid and ferritin in the development and progression of NAFLD[J].Int J Mol Sci,2016,17(4):548.
[16]白俊玺,舒仁明,黄勇,等.血尿酸与非酒精性脂肪性肝病发生风险相关性随访队列研究[J].中华肝脏病杂志,2018,26(4):271-275.
[17]Romero G,Zelber S,T reneli M.Treatment of NAFLD with diet,physical activity and exercise[J].J Hepatol,2017,67(4):829-846.
[2]Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia[J].J Hepatol,2017,67(4):862-873.
[3]Chao Y,Yang SJ,Xu WW,et al.Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population:a retrospective cohort study[J].PLoS One,2017,12(5):e0177249.
[4]中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].现代医药卫生,2018,34(5):641-649.
[5]Ivana M,Sandra M,Tamara TW,et al.Nonalcoholic fatty liver disease——a multisystem disease?[J].World J Gastroenterol,2016,22(43):9488-9505.
[6]Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.
[7]Zhu JZ,Zhou QY,Wang YE,et al.Prevalence of fatty liver disease and the economy in China:a systematic review[J].World J Gastroenterol,2015,21(18):5695-5706.
[8]Kwok R,Choi KC,Wong GL,et al.Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:a prospective cohort study[J].Gut,2016,65(8):1359-1368.
[9]Zhang RN,Zhang RD,Mi YQ,et al.APOC3 rs2070666 is associated with the severity of hepatic steatosis independently of PNPLA3 rs738409 in Chinese patients with nonalcoholic fatty liverdiseases[J].Dig Dis Sci,2016,61(8):2284-2293.
[10]Bedossa P,Flip Pathology Consortium.Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis,activity,and fibrosis(SAF)score in the evaluation of biopsies of nonalcoholic fatty liver disease[J].Hepatology,2014,60(2):565-575.
[11]Chitturi S,Wong VW,Chan WK,et al.The Asia Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 2:management and special groups[J].J Gastroenterol Hepatol,2018,33(1):86-98.
[12]Xu L,Lu W,Li P,et al.A comparison of hepatic steatosis index,controlled attenuation parameter,and ultrasound as noninvasive diagnostic tools for hepatic steatosis in patients with biopsy-proven chronic hepatitis B[J].Dig Liver Dis,2017,49(8):910-917.
[13]Zhang HJ,Pan LL,Ma ZM,et al.Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults:a 1-year follow up study[J].Diabetes Obes Metab,2017,19(2):284-289.
[14]Zheng XY,Gong LL,Luo R,et al.Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J].Lipids Health Dis,2017,16(10):202.
[15]Rosa L,Giuseppina P,Silvia F.Role of serum uric acid and ferritin in the development and progression of NAFLD[J].Int J Mol Sci,2016,17(4):548.
[16]白俊玺,舒仁明,黄勇,等.血尿酸与非酒精性脂肪性肝病发生风险相关性随访队列研究[J].中华肝脏病杂志,2018,26(4):271-275.
[17]Romero G,Zelber S,T reneli M.Treatment of NAFLD with diet,physical activity and exercise[J].J Hepatol,2017,67(4):829-846.